Corbus Pharmaceuticals
CRBP

$51.70

4.8%

Market Cap: $623M

About: Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Employees: 19

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

156% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 16

100% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 6 (+3) [Q2]

42% more capital invested

Capital invested by funds: $341M [Q1] → $486M (+$145M) [Q2]

30% more funds holding

Funds holding: 82 [Q1] → 107 (+25) [Q2]

17.64% more ownership

Funds ownership: 82.95% [Q1] → 100.59% (+17.64%) [Q2]

4% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 24

22% less call options, than puts

Call options by funds: $1.19M | Put options by funds: $1.52M

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$80

55%

upside

Avg. target

$82

59%

upside

High target

$88

70%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

RBC Capital Brian Abrahams 49% 1-year accuracy 38 / 77 met price target	59%upside $82	Outperform Reiterated	28 Aug 2024
RBC Capital Brian Abrahams 49% 1-year accuracy 38 / 77 met price target	59%upside $82	Outperform Reiterated	7 Aug 2024
Oppenheimer Jeff Jones 67% 1-year accuracy 20 / 30 met price target	70%upside $88	Outperform Maintained	7 Aug 2024
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 76 / 164 met price target	55%upside $80	Buy Reiterated	6 Aug 2024
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 76 / 164 met price target	55%upside $80	Buy Reinstated	22 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CRBP published over the past 30 days

24/7 Wall Street

3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024

The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry.

3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Zacks Investment Research

Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee.

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Zacks Investment Research

Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why

Corbus Pharmaceuticals (CRBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why

Zacks Investment Research

Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade

The consensus price target hints at a 54.2% upside potential for Corbus Pharmaceuticals (CRBP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024.

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events.

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet

Prospects for interest rate cuts are fueling speculations about which small-cap stocks will be winners when they hit. Because smaller companies don't have the same financial access as larger stocks, they are forced to borrow money at higher cost, which impacts their ability to grow.

Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Corbus Pharmaceuticals Holdings, Inc. reported positive results achieved in phase 1 China study, using CRB-701 for patients with mUC and cervical cancer; 44% and 43% ORR achieved for each, respectively. The global urothelial carcinoma market is expected to reach $6.82 billion in 2032. It is expected that the global cervical cancer treatment market could reach $12.63 billion by 2030.

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

See News Rankings